



## Clinical trial results:

### A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy

#### Summary

EudraCT number	2016-002554-21
Trial protocol	GB DE AT ES GR FR IT
Global end of trial date	07 February 2020

#### Results information

Result version number	v1
This version publication date	24 September 2020
First version publication date	24 September 2020

#### Trial information

##### Trial identification

Sponsor protocol code	251PP301
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03068468
WHO universal trial number (UTN)	-
Other trial identifiers	Bristol-Myers Squibb: CN002-012

Notes:

##### Sponsors

Sponsor organisation name	Biogen
Sponsor organisation address	250 Binney Street, Cambridge, United States, 02142
Public contact	Biogen Study Medical Director, Biogen, clinicaltrials@biogen.com
Scientific contact	Biogen Study Medical Director, Biogen, clinicaltrials@biogen.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 February 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	07 February 2020
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of BIIB092, relative to placebo, by measuring the frequency of deaths, SAEs, and AEs leading to discontinuation, and Grade 3 & 4 laboratory abnormalities.

Protection of trial subjects:

Written informed consent was obtained from each subject or subject's legally authorized representative (e.g., parent or legal guardian), as applicable, prior to evaluations performed for eligibility. Subjects or the subject's legally authorized representative were given adequate time to review the information in the informed consent/assent and were allowed to ask, and have answered, questions concerning all portions of the conduct of the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 June 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 129
Country: Number of subjects enrolled	Germany: 81
Country: Number of subjects enrolled	Spain: 65
Country: Number of subjects enrolled	France: 64
Country: Number of subjects enrolled	Japan: 39
Country: Number of subjects enrolled	United Kingdom: 26
Country: Number of subjects enrolled	Italy: 25
Country: Number of subjects enrolled	Canada: 16
Country: Number of subjects enrolled	Russian Federation: 16
Country: Number of subjects enrolled	Austria: 13
Country: Number of subjects enrolled	Korea, Republic of: 8
Country: Number of subjects enrolled	Greece: 7
Country: Number of subjects enrolled	Australia: 1
Worldwide total number of subjects	490
EEA total number of subjects	281

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	119
From 65 to 84 years	371
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Subjects were enrolled at 89 investigative sites in the United States, Australia, Austria, Canada, France, Germany, Greece, Italy, Japan, Republic of Korea, Russia Federation, Spain and United Kingdom from June 01, 2017 to February 07, 2020.

### Pre-assignment

Screening details:

A total of 490 subjects were enrolled in the study and out of that 486 were treated. The study had two periods, Placebo-controlled (PC) and open-label extension (OLE) period.

### Period 1

Period 1 title	Placebo-Controlled Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	BIIB092 Late Start

Arm description:

Subjects assigned to BIIB092 matching placebo intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 milligrams per millilitre (mg/mL) IV infusion once every 4 weeks starting at Week 52 in the OLE period.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects assigned to BIIB092 matching placebo IV infusion once every 4 weeks for 48 weeks.

Investigational medicinal product name	BIIB092
Investigational medicinal product code	BIIB092
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects assigned to BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52.

<b>Arm title</b>	BIIB092 Early Start
------------------	---------------------

Arm description:

Subjects assigned to BIIB092 50 mg/mL IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52 in the OLE period.

Arm type	Experimental
Investigational medicinal product name	BIIB092
Investigational medicinal product code	BIIB092
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Subjects assigned to BIIB092 50 mg/mL IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52 in the OLE period.

<b>Number of subjects in period 1</b> <sup>[1]</sup>	BIIB092 Late Start	BIIB092 Early Start
Started	165	321
Completed	144	279
Not completed	21	42
Consent withdrawn by subject	3	11
Adverse Event	16	21
Death	-	1
Withdrawal by Parent/Guardian	1	2
Reason not specified	1	6
Lack of efficacy	-	1

**Notes:**

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The number of subjects who started the baseline period are the subjects who were treated in the study.

**Period 2**

Period 2 title	Open-Label Extension Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

**Arms**

Are arms mutually exclusive?	Yes
<b>Arm title</b>	BIIB092 Late Start

**Arm description:**

Subjects assigned to BIIB092 matching placebo intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 milligrams per milliliter (mg/mL) IV infusion once every 4 weeks starting at Week 52 in the OLE period.

Arm type	Experimental
Investigational medicinal product name	BIIB092
Investigational medicinal product code	BIIB092
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Subjects assigned to BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52.

Investigational medicinal product name	Placebo
Investigational medicinal product code	BIIB092
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects assigned to BIIB092 matching placebo IV infusion once every 4 weeks for 48 weeks.

<b>Arm title</b>	BIIB092 Early Start
------------------	---------------------

Arm description:

Subjects assigned to BIIB092 50 mg/mL IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52 in the OLE period.

Arm type	Experimental
Investigational medicinal product name	BIIB092
Investigational medicinal product code	BIIB092
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects assigned to BIIB092 50 mg/mL IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52 in the OLE period.

<b>Number of subjects in period 2<sup>[2]</sup></b>	BIIB092 Late Start	BIIB092 Early Start
Started	140	276
Completed	0	0
Not completed	140	276
Consent withdrawn by subject	7	20
Failure to meet randomization criteria	2	-
Adverse Event	13	17
Death	-	1
Withdrawal by Parent/Guardian	-	4
Lost to follow-up	1	-
Reason not specified	1	4
Withdrawal by sponsor	115	228
Lack of efficacy	1	2

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: The number of subjects starting the open-label extension period is not same as the number of subjects who completed the placebo controlled period because few of the subjects did not enter the open-label extension period.

## Baseline characteristics

### Reporting groups

Reporting group title	BIIB092 Late Start
-----------------------	--------------------

Reporting group description:

Subjects assigned to BIIB092 matching placebo intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 milligrams per millilitre (mg/mL) IV infusion once every 4 weeks starting at Week 52 in the OLE period.

Reporting group title	BIIB092 Early Start
-----------------------	---------------------

Reporting group description:

Subjects assigned to BIIB092 50 mg/mL IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52 in the OLE period.

Reporting group values	BIIB092 Late Start	BIIB092 Early Start	Total
Number of subjects	165	321	486
Age categorical Units: Subjects			
Age Continuous Units: years			
arithmetic mean	68.9	68.7	-
standard deviation	± 6.57	± 7.02	-
Sex: Female, Male Units: subjects			
Female	74	136	210
Male	91	185	276
Race Units: Subjects			
White	138	281	419
Black or African American	1	1	2
Asian Indian	3	3	6
Chinese	0	1	1
Japanese	16	23	39
Asian Other	4	10	14
Unknown	3	2	5
Ethnicity Units: Subjects			
Hispanic or Latino	5	7	12
Not Hispanic or Latino	117	242	359
Unknown or Not Reported	43	72	115

## End points

### End points reporting groups

Reporting group title	BIIB092 Late Start
-----------------------	--------------------

Reporting group description:

Subjects assigned to BIIB092 matching placebo intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 milligrams per millilitre (mg/mL) IV infusion once every 4 weeks starting at Week 52 in the OLE period.

Reporting group title	BIIB092 Early Start
-----------------------	---------------------

Reporting group description:

Subjects assigned to BIIB092 50 mg/mL IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52 in the OLE period.

Reporting group title	BIIB092 Late Start
-----------------------	--------------------

Reporting group description:

Subjects assigned to BIIB092 matching placebo intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 milligrams per millilitre (mg/mL) IV infusion once every 4 weeks starting at Week 52 in the OLE period.

Reporting group title	BIIB092 Early Start
-----------------------	---------------------

Reporting group description:

Subjects assigned to BIIB092 50 mg/mL IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52 in the OLE period.

Subject analysis set title	BIIB092 Late Start
----------------------------	--------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

Subjects receiving at least one BIIB092 50 mg/mL IV infusion in the double blind treatment period, and if applicable, followed by BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52 in the open label extension period.

Subject analysis set title	BIIB092 Early Start
----------------------------	---------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

Subjects receiving at least one BIIB092 50 mg/mL IV infusion in the double blind treatment period, and if applicable, followed by BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52 in the open label extension period.

### Primary: Change From Baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at Week 52

End point title	Change From Baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at Week 52
-----------------	--

End point description:

The PSPRS is a quantitative measure of disability in participants with PSP. The PSPRS comprises 28 items in 6 areas. Six items are rated on a 3-point scale (0-2) and 22 are rated on a 5-point scale (0-4). The 6 areas are the History/Daily Activities, Mentation, Bulbar, Ocular Motor, Limb Motor, and Gait. The 28-item PSPRS total score ranges from 0 (normal) to 100. Fifteen items are selected to form a 15-item PSPRS and three domains are identified: Gait/Limb function, Ocular Motor, and Bulbar. The total 15-item PSPRS score ranges from 0 (normal) to 52. A positive change from baseline indicates worsening. Intent-to-Treat (ITT) population included randomized subjects who had received at least 1 dose of blinded study treatment (BIIB092 or Placebo).

End point type	Primary
----------------	---------

End point timeframe:

Baseline, Week 52

<b>End point values</b>	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139 <sup>[1]</sup>	278 <sup>[2]</sup>		
Units: Score on a scale				
arithmetic mean (standard error)				
PSPRS: 28 items	10.6 (± 0.8)	10.4 (± 0.6)		
PSPRS: 15 items	7.57 (± 0.52)	7.29 (± 0.38)		

Notes:

[1] - 'Number of Subjects Analyzed' signifies number of subjects who had response on Week 52.

[2] - 'Number of Subjects Analyzed' signifies number of subjects who had response on Week 52.

## Statistical analyses

<b>Statistical analysis title</b>	28-items
-----------------------------------	----------

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on a mixed model for repeated measures model (MMRM), with change from baseline in 28-item PSPRS total score as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline 28-item PSPRS, baseline 28-item PSPRS by time interaction, baseline Color Trails 2 test ( $\leq 170$  or  $> 170$  seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	417
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8483
Method	Mixed model for repeated measures (MMRM)
Parameter estimate	Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2
upper limit	1.6

<b>Statistical analysis title</b>	15-items
-----------------------------------	----------

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in 15-item PSPRS total score as dependent variable and with fixed effects of treatment group, time (categorical), treatment group by-time interaction, baseline 15-item PSPRS, baseline 15-item PSPRS by time interaction, baseline Color Trails 2 test ( $\leq 170$  or  $> 170$  seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	417
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6503
Method	MMRM
Parameter estimate	Difference
Point estimate	-0.28

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	0.94

**Primary: Percentage of Subjects with Death, Serious Adverse Events (SAEs), Adverse Events (AEs) and Adverse Events (AEs) Leading to Discontinuation of Drug**

End point title	Percentage of Subjects with Death, Serious Adverse Events (SAEs), Adverse Events (AEs) and Adverse Events (AEs) Leading to Discontinuation of Drug <sup>[3]</sup>
-----------------	---

End point description:

AEs: any sign, symptom, or diagnosis/disease that is unfavorable or unintended, that is new, or if pre-existing, worsens in subjects administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. SAEs: an event that results in death; an event that, in the view of the investigator, places the subject at immediate risk of death (a life-threatening event); an outcome that results in a congenital anomaly/birth defect diagnosed in a child of a subject; an event that requires or prolongs inpatient hospitalization; an event that results in persistent or significant disability/incapacity. Safety population included all randomized subjects who had received at least one dose of study treatment (BII092 or Placebo).

End point type	Primary
----------------	---------

End point timeframe:

up to 52 weeks

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistical analysis was planned to be reported for this endpoint.

End point values	BII092 Late Start	BII092 Early Start		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	162	324		
Units: Percentage of subjects				
number (not applicable)				
Death	4.9	4.9		
SAEs	32.1	27.2		
AEs	93.2	92.9		
AEs Leading to Discontinuation of Drug	11.1	7.4		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Change From Baseline in Movement Disorder Society (MDS)-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II at Week 52**

End point title	Change From Baseline in Movement Disorder Society (MDS)-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II at Week 52
-----------------	---

End point description:

The MDS-UPDRS Part 2 includes 13 items assessing motor aspects of experiences of daily living (M-

EDL) these include speech, saliva and drooling, chewing and swallowing, handwriting, doing hobbies and other activities, eating tasks, tremor, dressing, hygiene, turning in bed, getting out of bed, walking and balance, and freezing. All items have 5 responses with uniform anchors of 0= normal, 1= slight, 2= mild, 3= moderate, and 4= severe. Total score ranges from 0 to 52, higher score indicating severe conditions. A positive change from baseline indicates worsening. ITT population included randomized subjects who had received at least 1 dose of blinded study treatment (BII092 or Placebo).

End point type	Secondary
End point timeframe:	
Baseline, Week 52	

End point values	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	143 <sup>[4]</sup>	270 <sup>[5]</sup>		
Units: Score on a scale				
arithmetic mean (standard error)	6.7 (± 0.6)	7.0 (± 0.4)		

Notes:

[4] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

[5] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

## Statistical analyses

<b>Statistical analysis title</b>	BIIB092 Late Start vs BIIB092 Early Start
-----------------------------------	---

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in MDS-UPDRS as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline MDS-UPDRS, baseline MDS-UPDRS by time interaction, baseline Color Trails 2 test (<=170 or >170 seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	413
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6031
Method	MMRM
Parameter estimate	Difference
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	1.7

## Secondary: Clinical Global Impression of Change (CGI-C) Scale Score

End point title	Clinical Global Impression of Change (CGI-C) Scale Score
-----------------	--

End point description:

The CGI-C scale measures the change in the patient's clinical status from a specific point in time. Using a 7-point scale, ranging from 1 (very much improved) to 7 (very much worse), with a score of 4 indicating no change. ITT population included randomized subjects who had received at least 1 dose of blinded study treatment (BII092 or Placebo).

End point type	Secondary
End point timeframe:	
Week 52	

End point values	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	138 <sup>[6]</sup>	271 <sup>[7]</sup>		
Units: Score on a scale				
arithmetic mean (standard error)	5.3 (± 0.1)	5.2 (± 0.1)		

Notes:

[6] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

[7] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

### Statistical analyses

<b>Statistical analysis title</b>	BIIB092 Late Start vs BIIB092 Early Start
-----------------------------------	---

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with CGI-C as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline CGI-S, baseline CGI-S by time interaction, baseline Color Trails 2 test ( $\leq 170$  or  $> 170$  seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	409
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7743
Method	MMRM
Parameter estimate	Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.1

### Secondary: Change From Baseline in Progressive Supranuclear Palsy (PSP)- Cognitive Composite Battery Z-Score at Week 52

End point title	Change From Baseline in Progressive Supranuclear Palsy (PSP)- Cognitive Composite Battery Z-Score at Week 52
-----------------	--

End point description:

The PSP cognitive composite battery is used to identify and characterize abnormal cognitive decline in PSP subjects. The PSP cognitive composite battery includes 13 sub-tests in total: 11 tests from the RBANS (only the picture naming is excluded), letter number sequencing test, and phonemic fluency test. Three domains are identified: Memory and learning, Visual-Motor function, and Working memory and Executive. A z-score transformation is applied for each component test at each visit, and the final total composite z-score is the average of the three domain z-scores. A negative change from baseline indicates worsening ITT population included randomized subjects who had received at least 1 dose of blinded study treatment (BII092 or Placebo).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 52

<b>End point values</b>	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134 <sup>[8]</sup>	249 <sup>[9]</sup>		
Units: Score on a scale				
arithmetic mean (standard error)	-0.283 (± 0.032)	-0.245 (± 0.024)		

Notes:

[8] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

[9] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

## Statistical analyses

<b>Statistical analysis title</b>	BIIB092 Late Start vs BIIB092 Early Start
-----------------------------------	---

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in PSP-cognitive composite battery as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline PSP-cognitive composite battery, baseline PSP-cognitive composite battery by time interaction, baseline Color Trails 2 test ( $\leq 170$  or  $> 170$  seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	383
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.318
Method	MMRM
Parameter estimate	Difference
Point estimate	0.038
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.036
upper limit	0.112

## Secondary: Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Disease Severity (RBANS) Scale at Week 52

End point title	Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Disease Severity (RBANS) Scale at Week 52
-----------------	---

End point description:

The RBANS provides both a total scale score and scores for 5 different cognitive domains. Specifically, the test measures immediate memory, visuospatial/constructional ability, language, attention, and delayed memory. Scores from all subtests are aggregated into a total composite score. RBANS data were age-normed and analyzed as index scores (also referred to as standard scores), which have a mean of 100 and a standard deviation of 15. Higher scores on each sub measure and index indicate worsening. A negative change from baseline indicates better performance. ITT population included randomized subjects who had received at least 1 dose of blinded study treatment (BII092 or Placebo).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 52

<b>End point values</b>	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	111 <sup>[10]</sup>	222 <sup>[11]</sup>		
Units: Score on a scale				
arithmetic mean (standard error)	-3.1 (± 0.7)	-3.2 (± 0.5)		

Notes:

[10] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

[11] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

## Statistical analyses

<b>Statistical analysis title</b>	BIIB092 Late Start vs BIIB092 Early Start
-----------------------------------	---

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in RBANS as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline RBANS , baseline RBANS by time interaction, baseline Color Trails 2 test (<=170 or >170 seconds and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	333
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.827
Method	MMRM
Parameter estimate	Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	1.4

## Secondary: Change From Baseline in Progressive Supranuclear Palsy Quality of Life Scale (PSP-QoL) Score

End point title	Change From Baseline in Progressive Supranuclear Palsy Quality of Life Scale (PSP-QoL) Score
-----------------	--

End point description:

The PSP-QoL is a patient-reported outcome measure specifically for assessing the health-related quality of life in people living with PSP. It is validated 45-item questionnaire and visual analog scale (VAS) that is comprised of 2 subscales: physical health state (22 items), which covers mobility, dysarthria, dysphagia, visual disturbances, self-care and activities of daily living, and mental health state (23 items), which covers emotional, cognitive and social functioning. Items are given a 6-reponse option format (No Problem, Slight Problem, Moderate Problem, Marked Problem, Extreme Problem and Not Applicable). The subscale results are derived by summing the respective items for that subscale and transforming the scores into a range of 0 to 100, the higher the scores = greater impact of the disease. The PSP-QoL also comprises of a Life Satisfaction rating gauge, which is a VAS with a range of 0 (worst) to 100 (best). ITT population. Here, 'n' = number of subjects analyzed for each parameter.

End point type	Secondary
End point timeframe:	
Baseline, Week 52	

End point values	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	142 <sup>[12]</sup>	264 <sup>[13]</sup>		
Units: Score on a scale				
arithmetic mean (standard error)				
Physical Scale Score (n=142, 264)	11.3 (± 1.5)	11.2 (± 1.1)		
Mental Scale Score (n=140, 264)	5.6 (± 1.4)	6.1 (± 1.0)		
Satisfaction With Your Life Today(n=141,264)	-3.7 (± 1.8)	-5.4 (± 1.3)		

Notes:

[12] - 'Number of Subjects Analyzed' signifies number of subjects who had response on Week 52.

[13] - 'Number of Subjects Analyzed' signifies number of subjects who had response on Week 52.

## Statistical analyses

<b>Statistical analysis title</b>	BIIB092 Late Start vs BIIB092 Early Start
-----------------------------------	---

Statistical analysis description:

Physical scale score: Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in PSP-QoL as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for PSP-QoL, baseline PSP-QoL by time interaction, baseline Color Trails 2 test (<=170 or >170 seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	406
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9304
Method	MMRM
Parameter estimate	Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.6
upper limit	3.3

<b>Statistical analysis title</b>	BIIB092 Late Start vs BIIB092 Early Start
-----------------------------------	---

Statistical analysis description:

Mental scale score: Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in PSPQoL as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-bytime interaction, baseline for PSP-QoL, baseline PSP-QoL by time interaction, baseline Color Trails 2 test (<=170 or >170 seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
-------------------	--

Number of subjects included in analysis	406
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7859
Method	MMRM
Parameter estimate	Difference
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	3.7

<b>Statistical analysis title</b>	BIIB092 Late Start vs BIIB092 Early Start
-----------------------------------	---

Statistical analysis description:

Satisfaction With Your Life Today: Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in PSPQoL as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-bytime interaction, baseline for PSP-QoL, baseline PSP-QoL by time interaction, baseline Color Trails 2 test ( $\leq 170$  or  $> 170$  seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	406
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4297
Method	MMRM
Parameter estimate	Difference
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.8
upper limit	2.5

### **Secondary: Change From Baseline in Schwab and England Activities of Daily Living (SEADL) Scale Score at Week 48**

End point title	Change From Baseline in Schwab and England Activities of Daily Living (SEADL) Scale Score at Week 48
-----------------	--

End point description:

The SEADL scale is a means of assessing a person's ability to perform daily activities in terms of speed and independence, with 100% indicating total independence, falling to 0%, which indicates a state of complete dependence. The individual is asked to rate his or her function using an 11-point scale (10% increments), from 100% (completely independent; able to do all chores without slowness, difficulty, or impairment; essentially normal; unaware of any difficulty) to 0% (vegetative functions such as swallowing, bladder and bowels are not functioning; bedridden). A negative change from baseline indicates worsening. ITT population included randomized subjects who had received at least 1 dose of blinded study treatment (BIIB092 or Placebo).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 48

<b>End point values</b>	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	140 <sup>[14]</sup>	277 <sup>[15]</sup>		
Units: Score on a scale				
arithmetic mean (standard error)	-13.7 (± 1.4)	-11.7 (± 1.0)		

Notes:

[14] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

[15] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

## Statistical analyses

<b>Statistical analysis title</b>	BIIB092 Late Start vs BIIB092 Early Start
-----------------------------------	---

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in SEADL as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for SEADL, baseline SEADL by time interaction, baseline Color Trails 2 test (<=170 or >170 seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	417
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2084
Method	MMRM
Parameter estimate	Difference
Point estimate	2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	5.2

## Secondary: Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Week 52

End point title	Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Week 52
-----------------	---

End point description:

The Clinical Global Impression of Severity (CGI-S) Rating evaluates the severity of individual symptoms and treatment response in subjects with mental disorders. The CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms. ITT population included randomized subjects who had received at least 1 dose of blinded study treatment (BIIB092 or Placebo).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 52

<b>End point values</b>	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	140 <sup>[16]</sup>	269 <sup>[17]</sup>		
Units: Score on a scale				
arithmetic mean (standard error)	0.6 (± 0.1)	0.6 (± 0.0)		

Notes:

[16] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

[17] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

## Statistical analyses

<b>Statistical analysis title</b>	BIIB092 Late Start vs BIIB092 Early Start
-----------------------------------	---

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in CGI-S as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for CGI-S, baseline CGI-S by time interaction, baseline Color Trails 2 test (<=170 or >170 seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	409
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5701
Method	MMRM
Parameter estimate	Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.1

## Secondary: Change From Baseline in Phonemic Fluency Test Score at Week 48

End point title	Change From Baseline in Phonemic Fluency Test Score at Week 48
-----------------	--

End point description:

Phonemic fluency is a sensitive test for assessing frontal lobe dysfunction. Participants are given a letter of the alphabet and asked to name as many words as they can that start with that letter in 1 minute. The score for each trial is auto-calculated as follows: Trial 1: Total number of correct responses for the first letter (range 1 to 40); Trial 2: Total number of correct responses for the second letter (range 1 to 40). More number of words correlates to better phonemic fluency. A negative change from baseline indicates worsening. ITT population included randomized subjects who had received at least 1 dose of blinded study treatment (BII092 or Placebo).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 48

<b>End point values</b>	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	141 <sup>[18]</sup>	273 <sup>[19]</sup>		
Units: Score on a scale				
arithmetic mean (standard deviation)	-0.9 (± 0.4)	0.0 (± 0.3)		

Notes:

[18] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

[19] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

## Statistical analyses

<b>Statistical analysis title</b>	BIIB092(Late Start Vs Early Start)
Statistical analysis description:	
Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in Phonemic Fluency Test as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline Phonemic Fluency Test, baseline Phonemic Fluency Test by time interaction, baseline Color Trails 2 test (<=170 or >170 seconds) and region.	
Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	414
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0517
Method	MMRM
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	1.8

## Secondary: Change From Baseline in Letter-Number Sequencing Test at Week 48

<b>End point title</b>	Change From Baseline in Letter-Number Sequencing Test at Week 48
End point description:	
Letter number is a test of working memory which involves ordering a series of up to 8 letters and numbers in which the numbers are repeated back first in order starting with the lowest number, then followed by the letters in alphabetical order. Higher number of correct items is best and a negative change from baseline indicates worsening. ITT population included randomized subjects who had received at least 1 dose of blinded study treatment (BII092 or Placebo).	
End point type	Secondary
End point timeframe:	
Baseline, Week 48	

<b>End point values</b>	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139 <sup>[20]</sup>	271 <sup>[21]</sup>		
Units: Score on a scale				
arithmetic mean (standard error)	-1.9 (± 0.4)	-1.1 (± 0.3)		

Notes:

[20] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

[21] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

## Statistical analyses

<b>Statistical analysis title</b>	BIIB092 Late Start vs BIIB092 Early Start
Statistical analysis description:	
Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in Letter Number Sequence as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline Letter Number Sequence, baseline Letter Number Sequence by time interaction, baseline Color Trails 2 test ( $\leq 170$ or $> 170$ seconds) and region.	
Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	410
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0387
Method	MMRM
Parameter estimate	Difference
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	1.7

## Secondary: Change From Baseline in Color Trails at Week 48

<b>End point title</b>	Change From Baseline in Color Trails at Week 48
End point description:	
The Color Trails test is a language free version of the Trail Making Test and was developed to allow for broader cross-cultural assessment. For Part 1 (color trails test 1), the respondent uses a pencil to rapidly connect circles numbered 1-25 in sequence. For Part 2 (color trails test 2), the respondent rapidly connects number circles in sequence, but alternates between pink and yellow background. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors. Less time indicates better performance. A positive change from baseline indicates worsening. ITT population included randomized subjects who had received at least 1 dose of blinded study treatment (BII092 or Placebo).	
End point type	Secondary
End point timeframe:	
Baseline, Week 48	

<b>End point values</b>	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	143 <sup>[22]</sup>	279 <sup>[23]</sup>		
Units: Seconds				
arithmetic mean (standard error)				
Color Trails Test 1	16.8 (± 3.6)	16.9 (± 2.7)		
Color Trails Test 2	10.6 (± 2.4)	10.5 (± 1.8)		

Notes:

[22] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

[23] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

## Statistical analyses

<b>Statistical analysis title</b>	BIIB092 Late Start vs BIIB092 Early Start
-----------------------------------	---

Statistical analysis description:

Color Trails Test 1: Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in Color trails Test 1 as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for Color Trails Test 1, baseline Color Trails Test 1 by time interaction, baseline Color Trails 2 test ( $\leq 170$  or  $> 170$  seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	422
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9815
Method	MMRM
Parameter estimate	Difference
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.1
upper limit	8.3

<b>Statistical analysis title</b>	BIIB092 Late Start vs BIIB092 Early Start
-----------------------------------	---

Statistical analysis description:

Color Trails Test 2: Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in Color Trails Test 2 as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for Color Trails Test 2, baseline Color Trails Test 2 by time interaction, and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	422
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9869
Method	MMRM
Parameter estimate	Difference
Point estimate	0

Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.7
upper limit	5.6

### Secondary: Change From Baseline in Montreal Cognitive Assessment (MoCA) Score at Week 48

End point title	Change From Baseline in Montreal Cognitive Assessment (MoCA) Score at Week 48
-----------------	---

End point description:

The MOCA was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MOCA range from 0-30, with higher score being better performance. A negative change from baseline indicates worsening. ITT population included randomized subjects who had received at least 1 dose of blinded study treatment (BII092 or Placebo).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 48

End point values	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	136 <sup>[24]</sup>	264 <sup>[25]</sup>		
Units: Score on a scale				
arithmetic mean (standard error)	-1.0 (± 0.3)	-0.5 (± 0.2)		

Notes:

[24] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

[25] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint.

### Statistical analyses

Statistical analysis title	BIIB092 Late Start vs BIIB092 Early Start
----------------------------	---

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in MoCA as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for MoCA, baseline MoCA by time interaction, baseline Color Trails 2 test (<=170 or >170 seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1763
Method	MMRM
Parameter estimate	Difference
Point estimate	0.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	1.2

---

### Secondary: Number of Participants with Treatment Emergent Antibodies (anti-BIIB092) Positive Results in Serum

End point title	Number of Participants with Treatment Emergent Antibodies (anti-BIIB092) Positive Results in Serum
End point description:	ADA population – subset of the safety population with at least one evaluable post-baseline evaluable ADA samples.
End point type	Secondary
End point timeframe:	Up to Week 48

End point values	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	160 <sup>[26]</sup>	323 <sup>[27]</sup>		
Units: Subjects	7	0		

Notes:

[26] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint

[27] - 'Number of Subjects Analyzed' signifies the total number of subjects analyzed in this endpoint

### Statistical analyses

No statistical analyses for this end point

---

### Secondary: Change From Baseline of Brain Volumes as Determined by MRI at Week 52

End point title	Change From Baseline of Brain Volumes as Determined by MRI at Week 52
End point description:	A 3 dimension (3D) T1-weighted MRI was performed to estimate brain volumes (e.g., ventricles, whole brain, midbrain, pons, superior cerebellar peduncle, third ventricle, and frontal lobes). Efficacy MRI population is the subset of the ITT population who had a least one measurable brain volumetric measurement. Here, 'n' signifies the number of subjects analyzed for each parameter.
End point type	Secondary
End point timeframe:	Baseline, Week 52

<b>End point values</b>	BIIB092 Late Start	BIIB092 Early Start		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	114 <sup>[28]</sup>	238 <sup>[29]</sup>		
Units: Cubic centimeter (cm <sup>3</sup> )				
arithmetic mean (standard error)				
Ventricles Volume: Change at Week 52 (n =103,222)	3.823 (± 0.302)	3.802 (± 0.216)		
Whole Brain Volume: Change at Week 52(n =101,210)	-18.612 (± 1.296)	-19.126 (± 0.950)		
Midbrain Volume: Change at Week 52 (n =108, 224)	-0.116 (± 0.008)	-0.120 (± 0.006)		
Pons Volume: Change at Week 52 (n =100, 223)	-0.198 (± 0.017)	-0.198 (± 0.012)		
Cerebellar Peduncle Volume:ChangeWeek52(n=101,216)	-0.005 (± 0.002)	-0.004 (± 0.002)		
Third Ventricle Volume:Change at Week52(n=114,238)	0.140 (± 0.014)	0.146 (± 0.010)		
Frontal Lobe Volume: Change at Week 52 (n =89,178)	1.184 (± 0.279)	1.143 (± 0.205)		

Notes:

[28] - 'Number of Subjects Analyzed' signifies number of subjects who had response on Week 52.

[29] - 'Number of Subjects Analyzed' signifies number of subjects who had response on Week 52.

## Statistical analyses

<b>Statistical analysis title</b>	Ventricles Volume
Statistical analysis description:	
Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in MRI region as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for MRI region, baseline MRI region by time interaction, baseline Color Trails 2 test (<=170 or >170 seconds) and region.	
Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	352
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9527
Method	MMRM
Parameter estimate	Difference
Point estimate	-0.021
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.726
upper limit	0.684

<b>Statistical analysis title</b>	Whole Brain Volume
Statistical analysis description:	
Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in MRI region as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for MRI region, baseline MRI region by time interaction, baseline Color Trails 2 test (<=170 or >170 seconds) and region.	

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	352
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7357
Method	MMRM
Parameter estimate	Difference
Point estimate	-0.514
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.506
upper limit	2.478

<b>Statistical analysis title</b>	Midbrain Volume
-----------------------------------	-----------------

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in MRI region as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for MRI region, baseline MRI region by time interaction, baseline Color Trails 2 test ( $\leq 170$  or  $> 170$  seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	352
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6439
Method	MMRM
Parameter estimate	Difference
Point estimate	-0.004
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.023
upper limit	0.014

<b>Statistical analysis title</b>	Pons Volume
-----------------------------------	-------------

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in MRI region as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for MRI region, baseline MRI region by time interaction, baseline Color Trails 2 test ( $\leq 170$  or  $> 170$  seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
-------------------	--

Number of subjects included in analysis	352
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9864
Method	MMRM
Parameter estimate	Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.039
upper limit	0.04

<b>Statistical analysis title</b>	Cerebellar Peduncle Volume
-----------------------------------	----------------------------

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in MRI region as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for MRI region, baseline MRI region by time interaction, baseline Color Trails 2 test ( $\leq 170$  or  $> 170$  seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	352
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7529
Method	MMRM
Parameter estimate	Difference
Point estimate	0.001
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.004
upper limit	0.006

<b>Statistical analysis title</b>	Third Ventricle Volume
-----------------------------------	------------------------

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in MRI region as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for MRI region, baseline MRI region by time interaction, baseline Color Trails 2 test ( $\leq 170$  or  $> 170$  seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	352
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.685
Method	MMRM
Parameter estimate	Difference
Point estimate	0.006

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.025
upper limit	0.038

<b>Statistical analysis title</b>	Frontal Lobe Volume
-----------------------------------	---------------------

Statistical analysis description:

Adjusted mean for each treatment group, difference with Placebo, 95% confidence interval and p-value at each time point were based on an MMRM model, with change from baseline in MRI region as dependent variable and with fixed effects of treatment group, time (categorical), treatment group-by-time interaction, baseline for MRI region, baseline MRI region by time interaction, baseline Color Trails 2 test ( $\leq 170$  or  $> 170$  seconds) and region.

Comparison groups	BIIB092 Late Start v BIIB092 Early Start
Number of subjects included in analysis	352
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9
Method	MMRM
Parameter estimate	Difference
Point estimate	-0.041
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.68
upper limit	0.598

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

up to 140 weeks

Adverse event reporting additional description:

Safety population included all randomized subjects who had received at least one dose of study treatment (BII092 or Placebo).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.1
--------------------	------

### Reporting groups

Reporting group title	BIIB092 Early Start
-----------------------	---------------------

Reporting group description:

Subjects receiving at least one BIIB092 50 mg/mL IV infusion in the double blind treatment period, and if applicable, followed by BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52 in the open label extension period.

Reporting group title	BIIB092 Late Start
-----------------------	--------------------

Reporting group description:

Subjects receiving at least one BIIB092 50 mg/mL IV infusion in the double-blind treatment period, and if applicable, followed by BIIB092 50 mg/mL IV infusion once every 4 weeks starting at Week 52 in the open label extension period.

<b>Serious adverse events</b>	BIIB092 Early Start	BIIB092 Late Start	
Total subjects affected by serious adverse events			
subjects affected / exposed	129 / 324 (39.81%)	82 / 162 (50.62%)	
number of deaths (all causes)	32	18	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast neoplasm			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer			

subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma in situ			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic gastric cancer			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma			
subjects affected / exposed	1 / 324 (0.31%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Pituitary tumour benign			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	1 / 324 (0.31%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Aortic aneurysm			

subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	2 / 324 (0.62%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	1 / 324 (0.31%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Cyst			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	4 / 324 (1.23%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 4	0 / 1	
Drowning			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Euthanasia			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gait disturbance			

subjects affected / exposed	2 / 324 (0.62%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	1 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gait inability</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>General physical health deterioration</b>			
subjects affected / exposed	1 / 324 (0.31%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Multiple organ dysfunction syndrome</b>			
subjects affected / exposed	1 / 324 (0.31%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
<b>Systemic inflammatory response syndrome</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Reproductive system and breast disorders</b>			
<b>Acquired phimosis</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Benign prostatic hyperplasia</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Prostatitis</b>			
subjects affected / exposed	2 / 324 (0.62%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory, thoracic and mediastinal</b>			

disorders			
Acute respiratory failure			
subjects affected / exposed	6 / 324 (1.85%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Aspiration			
subjects affected / exposed	1 / 324 (0.31%)	3 / 162 (1.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 1	0 / 1	
Choking			
subjects affected / exposed	0 / 324 (0.00%)	2 / 162 (1.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 324 (0.31%)	2 / 162 (1.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Dyspnoea			
subjects affected / exposed	2 / 324 (0.62%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	18 / 324 (5.56%)	12 / 162 (7.41%)	
occurrences causally related to treatment / all	0 / 19	0 / 15	
deaths causally related to treatment / all	0 / 2	0 / 5	
Pneumothorax			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Pulmonary embolism			
subjects affected / exposed	3 / 324 (0.93%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Pulmonary oedema			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory arrest			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory depression			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Respiratory distress			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	1 / 324 (0.31%)	3 / 162 (1.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Psychiatric disorders			
Agitation			
subjects affected / exposed	1 / 324 (0.31%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Assisted suicide			

subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Confusional state</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hallucination</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Insomnia</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Mental status changes</b>			
subjects affected / exposed	2 / 324 (0.62%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Suicidal ideation</b>			
subjects affected / exposed	3 / 324 (0.93%)	2 / 162 (1.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Suicide attempt</b>			
subjects affected / exposed	2 / 324 (0.62%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Investigations</b>			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			

subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test increased			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar puncture			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical vertebral fracture			
subjects affected / exposed	5 / 324 (1.54%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	1 / 324 (0.31%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			

subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Facial bones fracture		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Fall		
subjects affected / exposed	49 / 324 (15.12%)	17 / 162 (10.49%)
occurrences causally related to treatment / all	0 / 56	0 / 19
deaths causally related to treatment / all	0 / 0	0 / 0
Femoral neck fracture		
subjects affected / exposed	3 / 324 (0.93%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Femur fracture		
subjects affected / exposed	3 / 324 (0.93%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Fracture		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Hip fracture		
subjects affected / exposed	2 / 324 (0.62%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Human bite		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1
Humerus fracture		

subjects affected / exposed	2 / 324 (0.62%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Joint dislocation		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Lumbar vertebral fracture		
subjects affected / exposed	1 / 324 (0.31%)	2 / 162 (1.23%)
occurrences causally related to treatment / all	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Musculoskeletal foreign body		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Open globe injury		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Periprosthetic fracture		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Post procedural haemorrhage		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Radius fracture		
subjects affected / exposed	3 / 324 (0.93%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Rib fracture		

subjects affected / exposed	4 / 324 (1.23%)	3 / 162 (1.85%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scapula fracture			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin laceration			
subjects affected / exposed	4 / 324 (1.23%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	3 / 324 (0.93%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	1 / 324 (0.31%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	2 / 324 (0.62%)	2 / 162 (1.23%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon injury			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			

subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic vertebral fracture			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haematoma			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic intracranial haemorrhage			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrong dose			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			

subjects affected / exposed	0 / 324 (0.00%)	2 / 162 (1.23%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Atrial fibrillation		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Atrioventricular block complete		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Atrioventricular block second degree		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Cardiac arrest		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Cardiac failure		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Cardio-respiratory arrest		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1
Hypertensive heart disease		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1
Myocardial ischaemia		

subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>Nervous system disorders</b>			
<b>Akathisia</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cerebral disorder</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cerebrovascular accident</b>			
subjects affected / exposed	3 / 324 (0.93%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Dyskinesia</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Encephalopathy</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Epilepsy</b>			
subjects affected / exposed	2 / 324 (0.62%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Lumbosacral radiculopathy</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Metabolic encephalopathy</b>			

subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Monoparesis		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Movement disorder		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Neurological decompensation		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1
Noninfective encephalitis		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	1 / 1
Peroneal nerve palsy		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Progressive supranuclear palsy		
subjects affected / exposed	10 / 324 (3.09%)	8 / 162 (4.94%)
occurrences causally related to treatment / all	0 / 10	0 / 9
deaths causally related to treatment / all	0 / 7	0 / 3
Seizure		
subjects affected / exposed	2 / 324 (0.62%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Somnolence		

subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Status epilepticus</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Subarachnoid haemorrhage</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Syncope</b>			
subjects affected / exposed	3 / 324 (0.93%)	2 / 162 (1.23%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Transient ischaemic attack</b>			
subjects affected / exposed	0 / 324 (0.00%)	2 / 162 (1.23%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Iron deficiency anaemia</b>			
subjects affected / exposed	1 / 324 (0.31%)	2 / 162 (1.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
<b>Colitis microscopic</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Constipation</b>			

subjects affected / exposed	1 / 324 (0.31%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Diarrhoea</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Dysphagia</b>			
subjects affected / exposed	7 / 324 (2.16%)	6 / 162 (3.70%)	
occurrences causally related to treatment / all	0 / 7	1 / 6	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Faecaloma</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Femoral hernia</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastritis</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hernial eventration</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hiatus hernia</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Large intestine polyp</b>			

subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Melaena</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Umbilical hernia</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Upper gastrointestinal haemorrhage</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Volvulus</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Vomiting</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hepatobiliary disorders</b>			
<b>Cholelithiasis</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Skin and subcutaneous tissue disorders</b>			
<b>Dermal cyst</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Renal and urinary disorders</b>			

Acute kidney injury			
subjects affected / exposed	3 / 324 (0.93%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urge incontinence			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	2 / 324 (0.62%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	2 / 324 (0.62%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondrocalcinosis			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma muscle			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle rigidity			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteitis			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abscess neck			
subjects affected / exposed	1 / 324 (0.31%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			

subjects affected / exposed	2 / 324 (0.62%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
<b>Bacterial infection</b>		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Bronchitis</b>		
subjects affected / exposed	3 / 324 (0.93%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Clostridium difficile colitis</b>		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Cystitis</b>		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Diverticulitis</b>		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Escherichia urinary tract infection</b>		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Gastroenteritis</b>		
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Infection</b>		

subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Influenza		
subjects affected / exposed	2 / 324 (0.62%)	1 / 162 (0.62%)
occurrences causally related to treatment / all	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Parainfluenzae virus infection		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumonia		
subjects affected / exposed	16 / 324 (4.94%)	5 / 162 (3.09%)
occurrences causally related to treatment / all	0 / 18	0 / 5
deaths causally related to treatment / all	0 / 4	0 / 0
Pneumonia influenzal		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Pulmonary sepsis		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Pulmonary tuberculosis		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0
Respiratory syncytial virus bronchitis		
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Respiratory tract infection		

subjects affected / exposed	2 / 324 (0.62%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Sepsis</b>			
subjects affected / exposed	4 / 324 (1.23%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>Septic shock</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Subcutaneous abscess</b>			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Urinary tract infection</b>			
subjects affected / exposed	5 / 324 (1.54%)	5 / 162 (3.09%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Urosepsis</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Viral infection</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Wound infection staphylococcal</b>			
subjects affected / exposed	1 / 324 (0.31%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Metabolism and nutrition disorders</b>			
Dehydration			

subjects affected / exposed	2 / 324 (0.62%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	0 / 324 (0.00%)	1 / 162 (0.62%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Failure to thrive			
subjects affected / exposed	2 / 324 (0.62%)	0 / 162 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	BIIB092 Early Start	BIIB092 Late Start	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	269 / 324 (83.02%)	143 / 162 (88.27%)	
Investigations			
Weight decreased			
subjects affected / exposed	23 / 324 (7.10%)	6 / 162 (3.70%)	
occurrences (all)	24	6	
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	58 / 324 (17.90%)	31 / 162 (19.14%)	
occurrences (all)	96	61	
Head injury			
subjects affected / exposed	27 / 324 (8.33%)	12 / 162 (7.41%)	
occurrences (all)	32	15	
Fall			
subjects affected / exposed	194 / 324 (59.88%)	96 / 162 (59.26%)	
occurrences (all)	497	295	
Skin abrasion			
subjects affected / exposed	35 / 324 (10.80%)	13 / 162 (8.02%)	
occurrences (all)	64	36	
Rib fracture			

subjects affected / exposed occurrences (all)	18 / 324 (5.56%) 20	12 / 162 (7.41%) 14	
Skin laceration subjects affected / exposed occurrences (all)	48 / 324 (14.81%) 68	24 / 162 (14.81%) 41	
Vascular disorders Haematoma subjects affected / exposed occurrences (all)	30 / 324 (9.26%) 49	16 / 162 (9.88%) 26	
Hypertension subjects affected / exposed occurrences (all)	9 / 324 (2.78%) 12	10 / 162 (6.17%) 10	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	20 / 324 (6.17%) 24	13 / 162 (8.02%) 17	
Headache subjects affected / exposed occurrences (all)	40 / 324 (12.35%) 68	23 / 162 (14.20%) 34	
General disorders and administration site conditions Oedema peripheral subjects affected / exposed occurrences (all)	21 / 324 (6.48%) 27	5 / 162 (3.09%) 6	
Gastrointestinal disorders Constipation subjects affected / exposed occurrences (all)	47 / 324 (14.51%) 57	18 / 162 (11.11%) 19	
Diarrhoea subjects affected / exposed occurrences (all)	30 / 324 (9.26%) 35	12 / 162 (7.41%) 17	
Dysphagia subjects affected / exposed occurrences (all)	22 / 324 (6.79%) 24	10 / 162 (6.17%) 10	
Respiratory, thoracic and mediastinal disorders Cough			

subjects affected / exposed occurrences (all)	19 / 324 (5.86%) 21	6 / 162 (3.70%) 7	
Dyspnoea subjects affected / exposed occurrences (all)	10 / 324 (3.09%) 11	9 / 162 (5.56%) 9	
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	18 / 324 (5.56%) 20	7 / 162 (4.32%) 7	
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	17 / 324 (5.25%) 18	8 / 162 (4.94%) 8	
Insomnia subjects affected / exposed occurrences (all)	24 / 324 (7.41%) 29	18 / 162 (11.11%) 18	
Suicidal ideation subjects affected / exposed occurrences (all)	19 / 324 (5.86%) 21	10 / 162 (6.17%) 14	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	21 / 324 (6.48%) 22	7 / 162 (4.32%) 9	
Back pain subjects affected / exposed occurrences (all)	24 / 324 (7.41%) 27	11 / 162 (6.79%) 19	
Musculoskeletal pain subjects affected / exposed occurrences (all)	22 / 324 (6.79%) 22	8 / 162 (4.94%) 9	
Pain in extremity subjects affected / exposed occurrences (all)	21 / 324 (6.48%) 22	7 / 162 (4.32%) 7	
Infections and infestations Bronchitis subjects affected / exposed occurrences (all)	19 / 324 (5.86%) 23	8 / 162 (4.94%) 11	

Nasopharyngitis			
subjects affected / exposed	36 / 324 (11.11%)	17 / 162 (10.49%)	
occurrences (all)	51	21	
Urinary tract infection			
subjects affected / exposed	78 / 324 (24.07%)	39 / 162 (24.07%)	
occurrences (all)	125	62	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 August 2017	Sponsor name from BMS to Biogen. This includes replacing the BMS title page with the Biogen title page, inserting the Biogen Sponsor Signature Page and Biogen Sponsor Information section, changing the compound name from BMS-986168 to BIIB092 throughout the document, and changing the study name from CN002012 to 251PP301.
13 September 2017	Sponsor name changed from BMS to Biogen. This includes replacing the BMS title page with the Biogen title page, inserting the Biogen Sponsor Signature Page and Biogen Sponsor Information section, changing the compound name from BMS-986168 to BIIB092 throughout the document, and changing the study name from CN002012 to 251PP301.
14 November 2017	Missing safety assessment, 12-lead electrocardiogram (ECG), and instruction to the assess infusion site to the double-blind schedule of events was added.
16 May 2018	Increase in the study sample size.
24 May 2018	An error was corrected in the decision criteria that would allow a subject who no longer has an active hepatitis C infection to enroll in the study.
01 February 2019	The study treatment product provided for use in the open-label extension period, to include the 2000 milligram per vial (mg/vial).

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Study got terminated as the primary endpoint was not met. PC period was completed at the time of termination. The study was not terminated due to a safety concern.

Notes: